Low LeverageA near-zero debt profile provides durable financial flexibility for a development-stage biotech. It lowers bankruptcy and interest-rate risk, preserves capacity to raise project financing or strike licensing/partnering deals without heavy debt servicing burdens over the next several months.

Prior Revenue Track RecordHistorical revenue in 2021–2022 indicates the company has demonstrated commercialization or monetization capability in the past. That track record can make future partnering, licensing, or targeted commercialization more credible to potential collaborators or investors over the medium term.

Lean Operating FootprintA very small headcount implies a lean cost base and lower fixed overhead, which helps stretch cash runway versus larger peers. For a biotech focused on R&D, a compact team can prioritize core programs and reduce nonessential burn while seeking partnerships or milestone financing.

Bears Say

Accelerating Cash BurnOperating cash flow has steeply deteriorated to -1.83B in 2025, with free cash flow similarly negative. Persistent and accelerating cash burn materially raises near-term financing needs, increasing the probability of dilution or distressed funding and constraining long-term program execution.

Eroded Shareholders' EquityA dramatic decline in equity over several years signals sustained losses that have depleted the balance-sheet cushion. Reduced equity limits the company’s ability to absorb further losses, lowers bargaining power with partners and lenders, and increases vulnerability to adverse funding outcomes.

No Recent Revenue & Widening LossesAbsence of meaningful revenue for multiple years alongside widening net losses to -1.72B in 2025 indicates the company remains pre-commercial and dependent on external capital. This undermines margin sustainability and places program progress at risk if financing or partnerships are delayed.

Delta-Fly Pharma, Inc. News

Delta-Fly Pharma’s Terminated Phase 3 AML Trial: What Investors Need to Know

Delta-Fly Pharma, Inc. ($JP:4598) announced an update on their ongoing clinical study. Study Overview This Phase 3 study,...

2M ago

4598

Delta-Fly Pharma’s Promising Clinical Study on Leukemia Treatment

Delta-Fly Pharma, Inc. (($JP:4598)) announced an update on their ongoing clinical study. Delta-Fly Pharma, Inc. is conducting a...

4M ago

4598

Delta-Fly Pharma’s Promising Phase 3 AML Study: A Potential Game Changer?

Delta-Fly Pharma, Inc. (($JP:4598)) announced an update on their ongoing clinical study. Delta-Fly Pharma, Inc. is conducting a...

4M ago

4598

Delta-Fly Pharma’s Promising Phase I Study on DFP-14927 for Solid Tumors

Delta-Fly Pharma, Inc. (($JP:4598)) announced an update on their ongoing clinical study. Delta-Fly Pharma, Inc. is conducting a...

4M ago

4598

4598 FAQ

What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?

Delta-Fly Pharma, Inc. lowest stock price was ¥213.00 and its highest was ¥793.00 in the past 12 months.

What is Delta-Fly Pharma, Inc.’s market cap?

Delta-Fly Pharma, Inc.’s market cap is ¥3.13B.

When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?

Delta-Fly Pharma, Inc.’s upcoming earnings report date is May 14, 2026 which is in 66 days.

How were Delta-Fly Pharma, Inc.’s earnings last quarter?

Delta-Fly Pharma, Inc. released its earnings results on Feb 13, 2026. The company reported -¥33.68 earnings per share for the quarter, missing the consensus estimate of N/A by -¥33.68.

Is Delta-Fly Pharma, Inc. overvalued?

According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Delta-Fly Pharma, Inc. pay dividends?

Delta-Fly Pharma, Inc. does not currently pay dividends.

What is Delta-Fly Pharma, Inc.’s EPS estimate?

Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Delta-Fly Pharma, Inc. have?

Delta-Fly Pharma, Inc. has 12,975,000 shares outstanding.

What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?

Delta-Fly Pharma, Inc. reported an EPS of -¥33.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.802%.

Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?

Currently, no hedge funds are holding shares in JP:4598

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.